About CereVasc
CereVasc is a company based in Auburndale (United States) founded in 2015 by Adel Malek, Patrick Sullivan, and Carl Heilman. CereVasc has raised $198.9 million across 3 funding rounds from investors including Bain Capital, Xontogeny and ATON Partners. CereVasc offers products and services including eShunt System. CereVasc operates in a competitive market with competitors including IRRAS, Tissuemed, Longeviti, Aqueduct Critical Care and NeuroDx, among others.
- Headquarter Auburndale, United States
- Founders Adel Malek, Patrick Sullivan, Carl Heilman
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cerevasc, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$198.9 M (USD)
in 3 rounds
-
Latest Funding Round
$85 M (USD), Series C
Jun 04, 2026
-
Investors
Bain Capital
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CereVasc
CereVasc offers a comprehensive portfolio of products and services, including eShunt System.
Minimally invasive device for treating hydrocephalus
People of CereVasc
Unlock access to complete
Funding Insights of CereVasc
CereVasc has successfully raised a total of $198.9M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $85 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CereVasc
CereVasc has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Bain Capital, Xontogeny and ATON Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life science startups are accelerated through focused programs by Xontogeny.
|
Locked | Locked | Locked | |
|
Debt and equity investments are pursued across multiple sectors.
|
Locked | Locked | Locked | |
|
Management consulting and investment guidance in medical technology are provided by ATON Partners.
|
Locked | Locked | Locked |
Investor details for CereVasc
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CereVasc
Investment portfolio details for CereVasc
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CereVasc
Detailed financials for CereVasc
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cerevasc Comparisons
Peer comparison for CereVasc
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CereVasc
CereVasc operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as IRRAS, Tissuemed, Longeviti, Aqueduct Critical Care and NeuroDx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of devices for fluid control and management after surgery
|
|
| Locked | Locked | Locked |
Bioadhesive films are developed to seal leaks in surgical procedures.
|
|
| Locked | Locked | Locked |
Implantable neurosurgical devices are developed for cranial defect correction.
|
|
| Locked | Locked | Locked |
Novel products to manage Cerebral Spinal Fluid (CSF) pressure
|
|
| Locked | Locked | Locked |
Medical devices for assessing shunt function in hydrocephalus patient.
|
Detailed competitors of CereVasc
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cerevasc
Complete news archive for CereVasc
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CereVasc
CereVasc was founded in 2015 and raised its 1st funding round 5 years after it was founded.
CereVasc is headquartered in Auburndale, United States. It is registered at Auburndale, Florida, United States.
Daniel Levangie is the current CEO of CereVasc.
CereVasc is a funded company, having raised a total of $198.9M across 3 funding rounds to date.
CereVasc was founded in 2015 and is based in Auburndale, United States. The company operates in the medical device sector, focusing on neurological conditions. A non-invasive cerebrospinal fluid shunt and catheter-based delivery system are being developed to treat communicating hydrocephalus, which impacts children and adults. Operations center on advancing this eShunt solution for clinical use.
CereVasc's top competitors include Tissuemed, Aqueduct Critical Care and IRRAS.
CereVasc offers eShunt System.
CereVasc has 8 investors. Key investors include Bain Capital, Xontogeny, ATON Partners, Piper Sandler, and Johnson & Johnson Innovation.